Related Experiment Videos
Augmented binding of radiolabeled monoclonal antibodies to melanoma cells using specific antibody combinations
K Mujoo1, M G Rosenblum, J L Murray
1Department of Clinical Immunology and Biological Therapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Abstract:
Antigenic heterogeneity may limit effective cancer therapy using monoclonal antibodies (Mabs). To address this problem, combinations of two, three, or four 125I-labeled antimelanoma Mabs (NRML-05, P94, 96.5, and CL207) were incubated in vitro with three different melanoma cell lines (HS294t, A375SM, and DX3). Binding of the various Mab combinations was expressed as total cpm/10(5) cells and was compared to binding of each Mab alone. Saturating amounts (10 micrograms/ml) of two, three, or four Mabs bound to a significantly greater extent (P less than 0.05) than each individual Mab except for NRML-05. Combinations of three Mabs at a nonsaturating concentration (1.5 micrograms/ml) bound to a greater extent than single Mabs (P less than 0.05), depending on the cell line examined and the amount of antigen sites present for each Mab. Saturating or nonsaturating concentrations of unlabeled Mab 96.5 combined with 125I-labeled NRML-05 enhanced binding of the latter to HS294t by significantly modifying its affinity and by increasing the number of binding sites 3-fold. Modulation occurred only at 37 degrees C and was dependent upon protein synthesis. These data demonstrate that the effectiveness of various Mab combinations over single Mabs varies, depending on Mab concentration and the cell lines used. In addition, one Mab may significantly (P less than 0.05) enhance binding of another Mab to its antigen.
Insights
Combining multiple monoclonal antibodies (Mabs) can improve melanoma cell binding compared to single Mabs. This approach shows promise for enhancing cancer therapy by overcoming antigenic heterogeneity.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Antigenic heterogeneity in cancer can impede effective therapy with monoclonal antibodies (Mabs).
- Developing combination therapies is crucial to overcome limitations of single-agent treatments.
Purpose of the Study:
- To investigate the efficacy of combining multiple antimelanoma monoclonal antibodies (Mabs) compared to single Mabs in vitro.
- To determine if Mab combinations can enhance binding to melanoma cells, addressing antigenic heterogeneity.
Main Methods:
- Incubation of 125I-labeled antimelanoma Mabs (NRML-05, P94, 96.5, CL207) in various combinations (two, three, or four) with three melanoma cell lines (HS294t, A375SM, DX3).
- Quantification of Mab binding using total counts per minute (cpm)/10(5) cells.
- Comparison of binding efficiency between Mab combinations and individual Mabs at saturating and nonsaturating concentrations.
Main Results:
- Combinations of two, three, or four Mabs showed significantly greater binding than individual Mabs at saturating concentrations (P < 0.05), except for NRML-05.
- At nonsaturating concentrations, three-Mab combinations demonstrated enhanced binding depending on the cell line and antigen availability (P < 0.05).
- Unlabeled Mab 96.5 significantly enhanced the binding of 125I-labeled NRML-05 to HS294t cells by increasing binding affinity and site number threefold, dependent on temperature (37°C) and protein synthesis.
Conclusions:
- The effectiveness of Mab combinations varies based on concentration and cell line, highlighting the need for tailored therapeutic strategies.
- Certain Mab combinations can significantly enhance binding to target antigens, suggesting a potential to overcome antigenic heterogeneity in melanoma.
- One Mab can modulate and enhance the binding of another Mab to its specific antigen, offering a novel approach for combination cancer immunotherapy.